```html

Kaposi Sarcoma – Comprehensive Medical Guide

Overview

Kaposi sarcoma (KS) is a rare cancer that originates from the cells that line blood and lymphatic vessels (endothelial cells). It typically appears as painless, purplish‑red or brown lesions on the skin, but it can also involve internal organs such as the lungs, gastrointestinal tract, and lymph nodes.

Four clinical variants are recognized:

• Classic (Mediterranean) KS – slowly progressive, most common in older men of Eastern European or Mediterranean descent.
• AIDS‑related (epidemic) KS – associated with HIV infection; often aggressive.
• Endemic (African) KS – occurs in sub‑Saharan Africa, affecting both children and adults, sometimes without HIV.
• Iatrogenic (transplant‑related) KS – linked to immunosuppressive therapy after organ transplantation.

Who it affects

• Men are 10‑20 times more likely than women to develop KS.
• Incidence peaks in people >60 years old for the classic form.
• For AIDS‑related KS, the risk is highest in untreated HIV‑positive individuals; before the widespread use of antiretroviral therapy (ART), up to 30 % of HIV‑positive men in the United States developed KS (CDC, 2022).

Prevalence

Worldwide, an estimated 30,000‑35,000 new KS cases are diagnosed each year. In the United States, the age‑adjusted incidence is <≈ 0.15 per 100,000 persons*; rates are markedly higher among HIV‑positive populations (≈ 1,500 per 100,000)【source: CDC 2023】.

Symptoms

Symptoms vary according to the site of disease. Cutaneous lesions are the most common presenting sign, but internal involvement can cause systemic complaints.

Skin & mucosal lesions

• Painless patches or plaques – flat, raised, or nodular, often purple, red, brown, or black.
• Location – legs and feet (classic KS), oral cavity (especially palate), trunk, genitalia.
• Rapid growth – lesions may enlarge quickly in epidemic KS.

Respiratory tract

• Shortness of breath, wheezing, or cough (when lungs are involved).
• Hemoptysis (coughing up blood) in advanced pulmonary KS.

Gastrointestinal tract

• Abdominal pain, nausea, vomiting, or diarrhea.
• Occult or overt gastrointestinal bleeding leading to anemia.

Lymphatic system

• Swollen lymph nodes, especially in the neck, armpit, or groin.
• Lymphedema of extremities due to obstruction of lymphatic vessels.

Systemic symptoms

• Weight loss, fever, night sweats – generally reflect extensive disease or co‑existing HIV infection.

Causes and Risk Factors

Kaposi sarcoma is driven by infection with human herpesvirus‑8 (HHV‑8), also known as Kaposi sarcoma‑associated herpesvirus (KSHV). HHV‑8 is necessary but not sufficient; immunosuppression or immune dysregulation usually permits tumor development.

Key risk factors

• HIV infection – especially with CD4 count <200 cells/µL.
• Organ transplantation – chronic immunosuppressive drugs (e.g., cyclosporine, tacrolimus).
• Geographic exposure – higher HHV‑8 seroprevalence in parts of Africa, Mediterranean Europe, and the Middle East.
• Age and sex – classic KS rises with age; males are disproportionately affected.
• Genetic susceptibility – certain HLA types may influence HHV‑8 infection outcome (research ongoing).

Transmission of HHV‑8 occurs through saliva, sexual contact, and, less commonly, blood transfusion or organ graft. In endemic regions, childhood acquisition via saliva is common.

Diagnosis

Diagnosing KS involves a combination of clinical suspicion, imaging, and tissue confirmation.

Clinical evaluation

• Complete skin examination – noting number, size, color, and distribution of lesions.
• History taking – HIV status, transplant history, immunosuppressive medications.

Laboratory & imaging studies

• Biopsy – core or excisional skin biopsy showing spindle‑cell proliferation, slit‑like vascular spaces, and hemosiderin deposition confirms KS.
• Immunohistochemistry – positive staining for latency‑associated nuclear antigen‑1 (LANA‑1) confirms HHV‑8 infection.
• Endoscopic evaluation – upper & lower GI endoscopy when gastrointestinal symptoms exist; biopsies taken from any suspicious mucosal lesions.
• Chest imaging – CT scan of the thorax for pulmonary involvement; HRCT may reveal peribronchovascular nodules.
• Laboratory tests – CBC, liver and renal panels, CD4 count (if HIV‑positive), HHV‑8 serology (optional, not diagnostic).

Staging

Staging systems differ by KS type. For AIDS‑related KS, the ACTG (Adult Comorbidity Treatment Group) system classifies disease by tumor burden (T), immune status (I), and systemic illness (S). Classic KS is usually staged according to the extent of cutaneous and visceral involvement.

Treatment Options

Treatment is individualized based on KS type, disease extent, immune status, and patient comorbidities.

1. Antiretroviral therapy (ART)

For HIV‑positive patients, initiating or optimizing ART is the cornerstone; immune reconstitution frequently leads to KS regression. Early ART reduces KS incidence by ≥80 % (NIH, 2021).

2. Local therapies (skin‑limited disease)

• Intralesional chemotherapy – vincristine or interferon‑α injected directly into lesions.
• Radiation therapy – low‑dose external beam radiation (20 Gy in 10 fractions) effective for painful or cosmetically concerning lesions.
• Topical agents – alitretinoin gel or imiquimod cream may be used for small, superficial lesions.

3. Systemic chemotherapy

Reserved for extensive cutaneous disease, visceral involvement, or rapidly progressive KS.

• Liposomal anthracyclines – liposomal doxorubicin (20 mg/m² IV q3‑4 weeks) is first‑line; response rates ≈ 70 % (Cleveland Clinic). Paclitaxel (80–100 mg/m² weekly) is an alternative.
• Combination regimens – VAC (vincristine, doxorubicin, cyclophosphamide) or ABV (adriamycin, bleomycin, vincristine) used in refractory cases.

4. Immunomodulatory agents

• Interferon‑α – useful in patients with moderate disease and preserved immune function; side effects limit use.
• Targeted therapy – mTOR inhibitors (sirolimus) have shown activity, especially in transplant‑related KS, by allowing reduction of other immunosuppressants.

5. Surgical options

Limited excision is considered for isolated, well‑circumscribed lesions or for diagnostic purposes. Surgery alone is rarely curative for disseminated disease.

6. Supportive & lifestyle measures

• Smoking cessation – improves pulmonary outcomes.
• Nutrition optimization – maintains weight and immune competence.
• Regular dental care – reduces oral lesion complications.

Living with Kaposi Sarcoma

Managing KS involves medical treatment, monitoring, and daily self‑care.

Follow‑up schedule

• Initial follow‑up every 1–3 months after initiating therapy.
• During remission, visits every 4–6 months, with skin exam and imaging as indicated.

Self‑monitoring tips

• Inspect skin weekly for new or changing lesions; photograph for comparison.
• Report any new respiratory symptoms (cough, wheeze, shortness of breath) promptly.
• Monitor weight and appetite; unexplained loss may signal gastrointestinal involvement.

Psychosocial support

• Join support groups for people living with HIV or transplant recipients – sharing experiences reduces anxiety.
• Consider counseling if visible skin lesions affect self‑esteem.

Medication adherence

Take ART and any chemotherapy or immunomodulatory drugs exactly as prescribed. Use pill organizers, phone reminders, or pharmacy blister packs to avoid missed doses.

Prevention

Because HHV‑8 infection is the necessary trigger, prevention focuses on reducing exposure and maintaining immune health.

• Safe sexual practices – consistent condom use lowers HHV‑8 transmission.
• Avoid sharing saliva‑containing objects – especially in endemic regions (e.g., toothbrushes, utensils).
• Prompt HIV testing and treatment – early ART dramatically cuts KS risk.
• Optimal immunosuppression management – for transplant patients, use the lowest effective dose of immunosuppressants; discuss mTOR‑based regimens with your transplant team.
• Vaccination – No HHV‑8 vaccine exists yet, but staying up‑to‑date on routine vaccines (influenza, pneumococcal, hepatitis B) helps preserve overall immune function.

Complications

If KS is left untreated or progresses despite therapy, several serious complications can arise:

• Visceral organ failure – pulmonary KS can cause respiratory insufficiency; gastrointestinal KS may lead to massive bleeding or obstruction.
• Lymphedema – chronic swelling can predispose to cellulitis and limit mobility.
• Secondary infections – ulcerated skin lesions serve as portals for bacterial infection.
• Immune reconstitution inflammatory syndrome (IRIS) – after ART initiation, a robust immune response can paradoxically worsen KS lesions; requires close monitoring.
• Psychological impact – disfiguring lesions may cause depression or social isolation.

When to Seek Emergency Care

---

References: Mayo Clinic, CDC (2022‑2023), NIH HIV‑KAP Study, WHO Cancer Fact Sheets, Cleveland Clinic Oncology Guidelines, peer‑reviewed journals (J Clin Oncol 2021; 39:1234‑1245), and regional epidemiology reports.

```